Launch of Innate Pharma's IPO on Eurolist C by Euronext in Paris
Registration of French "Document de base" with the AMF
IPH 1201 enters in pre-clinical and pharmaceutical development
Encouraging data on IPH 1101 with final results from phase I clinical trial in solid tumours
Financial results for the first half of 2006
New TLR assets from Schering-Plough Corporation and advanced R&D collaboration with IGR
Strategic partnership with Novo Nordisk to research and develop drugs targeting NK
Number of shares and voting rights, as of December 31, 2007
Refocus of partnership with Novo Nordisk A/S
Operating revenue of 14.2 million euros in 2007
